Northstar Advisory Group LLC raised its holdings in Stryker Co. (NYSE:SYK - Free Report) by 53.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,142 shares of the medical technology company's stock after purchasing an additional 3,519 shares during the quarter. Stryker accounts for 2.5% of Northstar Advisory Group LLC's investment portfolio, making the stock its 10th largest position. Northstar Advisory Group LLC's holdings in Stryker were worth $3,775,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Kohmann Bosshard Financial Services LLC bought a new position in Stryker in the 4th quarter valued at $25,000. Capital A Wealth Management LLC bought a new position in Stryker in the 4th quarter valued at $26,000. Rakuten Securities Inc. grew its stake in Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after purchasing an additional 68 shares during the period. Centricity Wealth Management LLC bought a new position in Stryker in the 4th quarter valued at $30,000. Finally, BankPlus Trust Department bought a new position in Stryker in the 4th quarter valued at $33,000. Institutional investors own 77.09% of the company's stock.
Stryker Price Performance
Shares of NYSE:SYK traded down $4.02 on Wednesday, hitting $381.03. The company's stock had a trading volume of 792,341 shares, compared to its average volume of 1,330,630. The company has a 50-day simple moving average of $371.23 and a 200 day simple moving average of $375.95. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a market capitalization of $145.43 billion, a PE ratio of 49.10, a PEG ratio of 2.93 and a beta of 0.91. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.
Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The firm had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. During the same quarter last year, the firm posted $2.50 EPS. The company's revenue was up 11.9% compared to the same quarter last year. Sell-side analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.
Stryker Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. Stryker's dividend payout ratio (DPR) is presently 45.41%.
Insider Activity
In related news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 5.90% of the company's stock.
Analyst Ratings Changes
A number of brokerages have recently commented on SYK. The Goldman Sachs Group set a $422.00 price target on Stryker in a research report on Tuesday, March 4th. BTIG Research set a $403.00 price target on Stryker and gave the company a "buy" rating in a research report on Monday, April 14th. Sanford C. Bernstein set a $450.00 price target on Stryker in a research report on Monday, May 5th. Wall Street Zen cut Stryker from a "buy" rating to a "hold" rating in a research report on Friday, June 6th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $427.30.
Read Our Latest Report on SYK
Stryker Company Profile
(
Free Report)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
See Also
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
